REG - Renalytix PLC - CEO Share Purchase

RenalytixAnnouncement

12/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260212:nRSL6759Sa&default-theme=true

RNS Number : 6759S  Renalytix PLC  12 February 2026

 

Renalytix plc

("Renalytix" or the "Company")

 

CEO Share Purchase

 

LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), a precision medicine diagnostics company, whose product
kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic
test to support early-stage risk assessment in chronic diabetic kidney
disease, announces that on 11 February 2026 James McCullough, Chief Executive
Officer, bought a total of 3,010 American Depositary Shares (ADS) at an
average price of US$3.01 per ADS. ADS consist of 50 Ordinary Shares of
£0.0025 each.

 

Following these purchases, James McCullough is interested in 3,392,596
Ordinary Shares(1) representing 0.78% of the issued share capital of the
Company.

 

(1)James McCullough shareholding includes ordinary shares held through his
family trust, The McCullough 2020 Irrevocable Trust.

 

For further information, please contact:

 

 Renalytix plc                                         www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                 Via Walbrook PR

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)             Tel: +44 (0)20 3470 0470
 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Joint Broker)                         Tel: +44 (0)20 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited        Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com
                            (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings                         Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About Renalytix (www.renalytix.com (http://www.renalytix.com) )

 

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled diabetic kidney disease remains one of the
largest barriers to controlling cost and suffering in the United States and
the United Kingdom's medical system, affecting approximately 15 million and 8
million people, respectively. After five years of development and clinical
validation, kidneyintelX.dkd is the only FDA-approved and Medicare-reimbursed
prognostic tool capable of understanding a patient's risk with diabetic kidney
disease early where treatment has maximal effect. kidneyintelX.dkd is now
being deployed across large physician group practices and health systems in
select regions of the United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix. For information about the
kidneyintelX,dkd test, visit kidneyintelx.com (http://kidneyintelx.com/) .

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         James McCullough

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Renalytix plc

 b)   LEI                                                          213800NTOH3FK3WER551

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  American Depository Shares (ADS) which consist of 50 Ordinary Shares at

                                                                 £0.0025 each

      Identification code                                          GB00BYWL4Y04

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                       Price(s)            Volume(s)
                                                                                       $3.74               10
                                                                                       $2.93               500
                                                                                       $3.01               500
                                                                                       $3.05               500
                                                                                       $3.05               500
                                                                                       $3.02               500
                                                                                       $3.01               500

 d)   Aggregated information

      - Aggregated volume                                          3,010
      - Price                                                      $9,072

 e)   Date of the transaction                                      11 February 2026

 f)   Place of the transaction                                     OTC New York

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUAOARNWUUAUR



            Copyright 2019 Regulatory News Service, all rights reserved